QNTM
Quantum Biopharma Subordinate Voting SharesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The constructive view is still narrow: Lucid-MS appears to be moving toward a planned Phase 2 pathway after the IND submission, and the May 7 operating update showed better liquidity and lower burn. If the IND path stays on track and financing pressure remains contained, QNTM can retain speculative upside from a very low base.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.9.
What can break
Clinical and regulatory timing risk around Lucid-MS IND review and planned Phase 2 execution. [#PR-EARNINGS-2026-05-07]
Momentum
2
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.35 · Bull $5.75 · Bear $2.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.50
Why
Momentum2 · Δ7d -0.4
Value41 · Δ7d -0.1
Sentiment74 · Δ7d +8.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
2
26% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-81.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
74
34% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
-26.1
Why this grade
Composite grade D. Momentum 1.9 / Value 41.1 / Sentiment 74.2
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$19.4M
Beta
0.79
Shares Out
6.4M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.94
Rev YoY
-
EPS YoY
-12.8%
Gross Margin
-
Op Margin
-
Net Debt
-$4.3M
Current Ratio
0.63
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology